Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

Mavenclad’s list price is £2,047.24 per 10mg tablet – a high price, but one that NHS England will have secured a discount on. In addition the outcomes-based agreement will mean the health ...